Autoimmune disorder of peripheral nervous system
MONDO:0000590A hypersensitivity reaction type II disease that involves the peripheral nervous system.
Also known as: peripheral nervous system autoimmune disease, peripheral nervous system hypersensitivity reaction type II disease
232 clinical trials for this condition and its sub-types, 0 tagged with Autoimmune disorder of peripheral nervous system itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Autoimmune disorder of peripheral nervous system
-
Myasthenia gravis 159 trials · 160 incl. sub-types
6 sub-types
- Juvenile myasthenia gravis 2 trials
- Adult-onset myasthenia gravis 0 trials
- Myasthenia gravis with thymus hyperplasia 0 trials
- Myasthenia, limb-girdle, autoimmune 0 trials
- Neonatal myasthenia gravis 0 trials
- Transient neonatal myasthenia gravis 0 trials
-
Guillain-Barre syndrome 23 trials · 39 incl. sub-types
11 sub-types
- Polyneuropathy, inflammatory demyelinating, chronic 15 trials
- Guillain-Barre syndrome, familial 1 trial
- Acute inflammatory demyelinating polyradiculoneuropathy 1 trial
- Autoimmune autonomic ganglionopathy 1 trial
- Acute motor and sensory axonal neuropathy 0 trials
- Acute motor axonal neuropathy 0 trials
- Acute pure sensory neuropathy 0 trials
- Acute sensory ataxic neuropathy 0 trials
- Facial diplegia with paresthesias 0 trials
- Paraparetic variant of Guillain-Barre syndrome 0 trials
- Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome 0 trials
-
Autoimmune neuropathy 1 trial
-
Autoimmune optic neuritis 0 trials
-
New drug batoclimab aims to ease muscle weakness in myasthenia gravis
Disease control Stopped earlyThis phase 3 trial tests batoclimab, a drug that blocks certain antibodies, in 240 adults with generalized myasthenia gravis (gMG). The study measures if batoclimab improves daily activities and muscle strength compared to a placebo. Participants receive injections weekly or bi-w…
Phase 3 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Experimental CAR t therapy for severe muscle weakness hits early hurdle
Disease control Stopped earlyThis early trial tested an experimental drug called HN2301, a type of CAR T cell therapy made inside the body, for people with refractory myasthenia gravis — a condition causing severe muscle weakness that doesn't respond well to standard treatments. The study planned to enroll 9…
Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Myasthenia gravis drug trial halted early – only 6 patients enrolled
Disease control Stopped earlyThis study tested tolebrutinib, an oral drug, in adults with moderate-to-severe generalized myasthenia gravis. The trial was a Phase 3, double-blind, placebo-controlled study that planned to enroll many participants but was terminated early with only 6 people enrolled. Because it…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 14:27 UTC
-
Abandoned trial: only 2 patients tested for stomach relief in muscle disease
Symptom relief Stopped earlyThis small, early-stage trial tested whether adding ondansetron (an anti-nausea drug) to pyridostigmine (a standard myasthenia gravis treatment) could reduce stomach side effects like nausea, vomiting, or diarrhea. Only 2 people with anti-AchR positive myasthenia gravis were enro…
Phase 2 • Sponsor: DAS-MG, Inc • Aim: Symptom relief
Last updated Jun 26, 2026 15:47 UTC
-
Biopsy tolerance study ends early – what we know
Knowledge-focused Stopped earlyThis study aimed to understand how well patients tolerate biopsies for autoimmune diseases and whether they feel properly informed. It planned to enroll 505 people but was terminated early. The results may help improve patient experience with these common procedures.
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC